Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI).

Full DD Report for BCLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: BCLI)

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q1 2018 Results - Earnings Call Transcript
BrainStorm Cell Therapeutics Inc. (BCLI) Q1 2018 Results Earnings Conference Call May 14, 2018, 08:30 AM ET Executives Chaim Lebovits - CEO Eyal Rubin - CFO Ralph Kern - CMO & COO Analysts Jason McCarthy - Maxim Group David Bautz - Zacks Investment Research Daniel G...
Source: SeekingAlpha
Date: May, 14 2018 13:35
BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
NEW YORK, N.Y. and PETACH TIKVAH, Israel , May 14, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2018 . ...
Source: PR Newswire
Date: May, 14 2018 08:00
BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and PETACH TIKVAH, Israel , May 9, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will present data from the com...
Source: PR Newswire
Date: May, 09 2018 01:00
Today's Research Reports on Trending Tickers: Cel-Sci Corporation and Brainstorm Cell Therapeutics
NEW YORK, NY / ACCESSWIRE / May 8, 2018 / A strong performance by the energy sector lifted U.S. markets higher for the second consecutive session Monday as oil prices topped $70 a barrel. Investor attention will now shift to President Trump’s decision on the Iran nuclear accord on Tu...
Source: ACCESSWIRE IA
Date: May, 08 2018 08:30
Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
NEW YORK and PETACH TIKVAH, Israel , May 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its financial results for the first quarter ended...
Source: PR Newswire
Date: May, 08 2018 07:12
BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
NEW YORK and PETACH TIKVAH, Israel , May 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern , M.D., MHSc, Chief Operating Officer and Chief Medic...
Source: PR Newswire
Date: May, 01 2018 09:01
3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorm's ALS Adventure Moves Forward
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: April, 30 2018 08:00
BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
NEW YORK and PETACH TIKVAH, Israel , April 11, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at ...
Source: PR Newswire
Date: April, 11 2018 01:00
Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics' Setback
A nalysis focus: Sorrento Sorrento Therapeutics (SRNE) shares are down nearly 25%. Shares have been dragged lower by the convertible debt deal announced on Tuesday, as well as, a cautious article published on Seeking Alpha. The article published by J Capital raises sev...
Source: SeekingAlpha
Date: March, 29 2018 08:00
BrainStorm Cell Therapeutics' Phase 3 trial of NurOwn in ALS now open to Canadian patients
BrainStorm Cell Therapeutics (NASDAQ: BCLI ) amends the protocol of its Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) by opening the enrollment to Canada-based ALS patients. More news on: BrainStorm Cell Therapeutics Inc., Healthcare ...
Source: SeekingAlpha
Date: March, 28 2018 07:42

 


About BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

Logo for BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

BrainStorm Cell Therapeutics Inc. is a clinical stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company s current primary targets are Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig s disease and Parkinson s disease PD . These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.

 

 

 

Current Management

  • Anthony Fiorino / CEO
  • Chaim Lebovits / President
  • Liat Sossover / CFO
  • Adrian Harel / IR
  • Irit Arbel /
  • Mordechai Friedman /
  • Alon Pinkas /
  • Chen Schor /
  • Dr. Robert Shorr /
  • Malcolm Taub /

Current Share Structure

  • Market Cap: $61,977,630 - 03/20/2018
  • Issue and Outstanding: 19,070,040 - 03/06/2018

 


Recent Filings from (NASDAQ: BCLI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018

 

 


Daily Technical Chart for (NASDAQ: BCLI)

Daily Technical Chart for (NASDAQ: BCLI)


Stay tuned for daily updates and more on (NASDAQ: BCLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BCLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BCLI and does not buy, sell, or trade any shares of BCLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/